BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim Y, Griffin JM, Nor MNM, Zhang J, Freestone PS, Danesh-Meyer HV, Rupenthal ID, Acosta M, Nicholson LFB, O'Carroll SJ, Green CR. Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels. Neurotherapeutics 2017;14:1148-65. [PMID: 28560708 DOI: 10.1007/s13311-017-0536-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 González-Casanova J, Schmachtenberg O, Martínez AD, Sanchez HA, Harcha PA, Rojas-Gomez D. An Update on Connexin Gap Junction and Hemichannels in Diabetic Retinopathy. Int J Mol Sci 2021;22:3194. [PMID: 33801118 DOI: 10.3390/ijms22063194] [Reference Citation Analysis]
2 Shome A, Mugisho OO, Niederer RL, Rupenthal ID. Blocking the inflammasome: A novel approach to treat uveitis. Drug Discov Today 2021:S1359-6446(21)00306-8. [PMID: 34229084 DOI: 10.1016/j.drudis.2021.06.017] [Reference Citation Analysis]
3 Li Q, Li QQ, Jia JN, Liu ZQ, Zhou HH, Mao XY. Targeting gap junction in epilepsy: Perspectives and challenges. Biomed Pharmacother 2019;109:57-65. [PMID: 30396092 DOI: 10.1016/j.biopha.2018.10.068] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
4 Coutinho FP, Green CR, Acosta ML, Rupenthal ID. Xentry-Gap19 inhibits Connexin43 hemichannel opening especially during hypoxic injury. Drug Deliv Transl Res 2020;10:751-65. [PMID: 32318976 DOI: 10.1007/s13346-020-00763-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Peng B, Xu C, Wang S, Zhang Y, Li W. The Role of Connexin Hemichannels in Inflammatory Diseases. Biology (Basel) 2022;11:237. [PMID: 35205103 DOI: 10.3390/biology11020237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Yu H, Cao X, Li W, Liu P, Zhao Y, Song L, Chen J, Chen B, Yu W, Xu Y. Targeting connexin 43 provides anti-inflammatory effects after intracerebral hemorrhage injury by regulating YAP signaling. J Neuroinflammation 2020;17:322. [PMID: 33115476 DOI: 10.1186/s12974-020-01978-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Acosta ML, Mat Nor MN, Guo CX, Mugisho OO, Coutinho FP, Rupenthal ID, Green CR. Connexin therapeutics: blocking connexin hemichannel pores is distinct from blocking pannexin channels or gap junctions. Neural Regen Res 2021;16:482-8. [PMID: 32985469 DOI: 10.4103/1673-5374.290097] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
8 Cliff CL, Williams BM, Chadjichristos CE, Mouritzen U, Squires PE, Hills CE. Connexin 43: A Target for the Treatment of Inflammation in Secondary Complications of the Kidney and Eye in Diabetes. Int J Mol Sci 2022;23:600. [PMID: 35054783 DOI: 10.3390/ijms23020600] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ma S, Kim YS, Jung JM, Boggu PR, Kim SC, Kim IS, Jung YH. Total synthesis of chromanol 293B and cromakalim via stereoselective amination of chiral benzylic ethers. Tetrahedron Letters 2020;61:151431. [DOI: 10.1016/j.tetlet.2019.151431] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Laird DW, Lampe PD. Therapeutic strategies targeting connexins. Nat Rev Drug Discov 2018;17:905-21. [PMID: 30310236 DOI: 10.1038/nrd.2018.138] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 20.3] [Reference Citation Analysis]
11 Delvaeye T, Vandenabeele P, Bultynck G, Leybaert L, Krysko DV. Therapeutic Targeting of Connexin Channels: New Views and Challenges. Trends Mol Med 2018;24:1036-53. [PMID: 30424929 DOI: 10.1016/j.molmed.2018.10.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
12 Hertelendy P, Varga DP, Menyhárt Á, Bari F, Farkas E. Susceptibility of the cerebral cortex to spreading depolarization in neurological disease states: The impact of aging. Neurochem Int 2019;127:125-36. [PMID: 30336178 DOI: 10.1016/j.neuint.2018.10.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
13 Zhang NN, Zhang Y, Wang ZZ, Chen NH. Connexin 43: insights into candidate pathological mechanisms of depression and its implications in antidepressant therapy. Acta Pharmacol Sin 2022. [PMID: 35145238 DOI: 10.1038/s41401-022-00861-2] [Reference Citation Analysis]
14 Südkamp N, Shchyglo O, Manahan-Vaughan D. Absence of Pannexin 1 Stabilizes Hippocampal Excitability After Intracerebral Treatment With Aβ (1-42) and Prevents LTP Deficits in Middle-Aged Mice. Front Aging Neurosci 2021;13:591735. [PMID: 33796018 DOI: 10.3389/fnagi.2021.591735] [Reference Citation Analysis]
15 Louie HH, Shome A, Kuo CY, Rupenthal ID, Green CR, Mugisho OO. Connexin43 hemichannel block inhibits NLRP3 inflammasome activation in a human retinal explant model of diabetic retinopathy. Exp Eye Res 2021;202:108384. [PMID: 33285185 DOI: 10.1016/j.exer.2020.108384] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
16 Potter JA, Price GW, Cliff CL, Green CR, Squires PE, Hills CE. Collagen I Modifies Connexin-43 Hemichannel Activity via Integrin α2β1 Binding in TGFβ1-Evoked Renal Tubular Epithelial Cells. Int J Mol Sci 2021;22:3644. [PMID: 33807408 DOI: 10.3390/ijms22073644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 De Meulenaere V, Bonte E, Verhoeven J, Kalala Okito JP, Pieters L, Vral A, De Wever O, Leybaert L, Goethals I, Vanhove C, Descamps B, Deblaere K. Adjuvant therapeutic potential of tonabersat in the standard treatment of glioblastoma: A preclinical F98 glioblastoma rat model study. PLoS One 2019;14:e0224130. [PMID: 31634381 DOI: 10.1371/journal.pone.0224130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
18 Yang TT, Qian F, Liu L, Peng XC, Huang JR, Ren BX, Tang FR. Astroglial connexins in epileptogenesis. Seizure 2021;84:122-8. [PMID: 33348235 DOI: 10.1016/j.seizure.2020.11.022] [Reference Citation Analysis]
19 Squires PE, Price GW, Mouritzen U, Potter JA, Williams BM, Hills CE. Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney. Int J Mol Sci 2021;22:2809. [PMID: 33802083 DOI: 10.3390/ijms22062809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Yang SH, Clemett CA, Brimble MA, O'Carroll SJ, Harris PWR. Synthesis and biological evaluation of S-lipidated lipopeptides of a connexin 43 channel inhibitory peptide. RSC Med Chem 2020;11:1041-7. [PMID: 33479696 DOI: 10.1039/d0md00172d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
21 Mat Nor MN, Rupenthal ID, Green CR, Acosta ML. Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases. Int J Mol Sci 2021;22:1755. [PMID: 33578721 DOI: 10.3390/ijms22041755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Tittarelli A. Connexin channels modulation in pathophysiology and treatment of immune and inflammatory disorders. Biochim Biophys Acta Mol Basis Dis 2021;1867:166258. [PMID: 34450245 DOI: 10.1016/j.bbadis.2021.166258] [Reference Citation Analysis]
23 Mugisho OO, Green CR, Zhang J, Acosta ML, Rupenthal ID. Connexin43 hemichannels: A potential drug target for the treatment of diabetic retinopathy. Drug Discov Today 2019;24:1627-36. [PMID: 30690195 DOI: 10.1016/j.drudis.2019.01.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
24 Boal AM, Risner ML, Cooper ML, Wareham LK, Calkins DJ. Astrocyte Networks as Therapeutic Targets in Glaucomatous Neurodegeneration. Cells 2021;10:1368. [PMID: 34199470 DOI: 10.3390/cells10061368] [Reference Citation Analysis]
25 Sarrouilhe D, Dejean C, Mesnil M. Connexin43- and Pannexin-Based Channels in Neuroinflammation and Cerebral Neuropathies. Front Mol Neurosci 2017;10:320. [PMID: 29066951 DOI: 10.3389/fnmol.2017.00320] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
26 Lyon H, Shome A, Rupenthal ID, Green CR, Mugisho OO. Tonabersat Inhibits Connexin43 Hemichannel Opening and Inflammasome Activation in an In Vitro Retinal Epithelial Cell Model of Diabetic Retinopathy. Int J Mol Sci 2020;22:E298. [PMID: 33396676 DOI: 10.3390/ijms22010298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Mat Nor MN, Rupenthal ID, Green CR, Acosta ML. Connexin Hemichannel Block Using Orally Delivered Tonabersat Improves Outcomes in Animal Models of Retinal Disease. Neurotherapeutics 2020;17:371-87. [PMID: 31637594 DOI: 10.1007/s13311-019-00786-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
28 Ahmadian E, Eftekhari A, Samiei M, Maleki Dizaj S, Vinken M. The role and therapeutic potential of connexins, pannexins and their channels in Parkinson's disease. Cellular Signalling 2019;58:111-8. [DOI: 10.1016/j.cellsig.2019.03.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]